Human medicines European public assessment report (EPAR): Isentress, raltegravir, Date of authorisation: 19/12/2007, Revision: 43, Status: Authorised

Human medicines European public assessment report (EPAR): Ryzodeg, insulin degludec,insulin aspart, Date of authorisation: 21/01/2013, Revision: 14, Status: Authorised

CVMP recommendations on limited market classification and eligibility for authorisation under Article 23

Timetable: Post-authorisation safety study (PASS) protocols and final results

Timetable: Initial (Full) marketing authorisation application - ATMP

Organisation chart: Advisory functions

Need for maximum residue limit (MRL) evaluation for biological substances - Scientific guideline

Human medicines European public assessment report (EPAR): Vaxzevria (previously COVID-19 Vaccine AstraZeneca), COVID-19 Vaccine (ChAdOx1-S [recombinant]), Date of authorisation: 29/01/2021, Revision: 32, Status: Withdrawn

Herbal medicinal product: Hippocastani cortexArray, F: Assessment finalised

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 April 2024